Suven Life Sciences (SUVEN) Stock Overview
A clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel therapeutics for the treatment of neurodegenerative disorders in India, the United States, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
SUVEN Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Suven Life Sciences Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹356.10 |
| 52 Week High | ₹371.00 |
| 52 Week Low | ₹124.11 |
| Beta | 0.84 |
| 1 Month Change | 31.96% |
| 3 Month Change | 81.75% |
| 1 Year Change | 21.03% |
| 3 Year Change | 464.34% |
| 5 Year Change | 310.96% |
| Change since IPO | 2.33% |
Recent News & Updates
Recent updates
Shareholder Returns
| SUVEN | IN Life Sciences | IN Market | |
|---|---|---|---|
| 7D | 12.3% | 4.0% | -0.3% |
| 1Y | 21.0% | 2.7% | -1.4% |
Return vs Industry: SUVEN exceeded the Indian Life Sciences industry which returned 2.7% over the past year.
Return vs Market: SUVEN exceeded the Indian Market which returned -1.4% over the past year.
Price Volatility
| SUVEN volatility | |
|---|---|
| SUVEN Average Weekly Movement | 10.2% |
| Life Sciences Industry Average Movement | 5.4% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in IN Market | 9.2% |
| 10% least volatile stocks in IN Market | 3.9% |
Stable Share Price: SUVEN's share price has been volatile over the past 3 months compared to the Indian market.
Volatility Over Time: SUVEN's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of Indian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1989 | 138 | Venkat Jasti | www.suven.com |
Suven Life Sciences Limited, a clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel therapeutics for the treatment of neurodegenerative disorders in India, the United States, Europe, and internationally. The company engages in drug discovery and development of new chemical entities in central nervous system diseases. Its product candidates include Masupirdine (SUVN-502) for the treatment of Alzheimer disease and neuropsychiatric symptoms; Samelisant (SUVN-G3031), a histamine 3 receptor inverse agonist for treating sleep and cognitive disorders; and Ropanicant (SUVN-911), an Alpha4Beta2 nAChRs receptor antagonist for the treatment of depressive disorders.
Suven Life Sciences Limited Fundamentals Summary
| SUVEN fundamental statistics | |
|---|---|
| Market cap | ₹91.77b |
| Earnings (TTM) | -₹2.76b |
| Revenue (TTM) | ₹71.15m |
Is SUVEN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SUVEN income statement (TTM) | |
|---|---|
| Revenue | ₹71.15m |
| Cost of Revenue | ₹0 |
| Gross Profit | ₹71.15m |
| Other Expenses | ₹2.83b |
| Earnings | -₹2.76b |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -10.48 |
| Gross Margin | 100.00% |
| Net Profit Margin | -3,884.13% |
| Debt/Equity Ratio | 0% |
How did SUVEN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/15 11:54 |
| End of Day Share Price | 2026/07/15 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2026/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Suven Life Sciences Limited is covered by 8 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Rohit Bhat | 360 ONE Capital Market Private Limited |
| Foram Parekh | BOB Capital Markets Ltd. |
| null null | DBS Bank Ltd |